Neupogen went off-patent in the US in 2013 ... Amgen has produced a long-lasting version known Neulasta (pegfilgrastim), which generates sales of just over a billion dollars per quarter.
The lack of competition for Neupogen in the US has propped up the ... white cell stimulator franchise from long-acting follow-up Neulasta (pegfilgrastim), which posted sales of $4.6 billion ...
Neulasta (pegfilgrastim) is a prescription drug used to help prevent infection from certain types of chemotherapy and to treat radiation sickness. Neulasta can interact with certain other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results